Product Overview

Vildalip 50 contains Vildagliptin, a selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the effective management of Type 2 Diabetes Mellitus. It is widely prescribed to improve blood glucose control in adults whose diabetes cannot be adequately managed through diet, exercise, and lifestyle modifications alone. With its proven clinical efficacy and favorable safety profile, Vildagliptin has become an important therapeutic option in modern diabetes care.

Vildalip 50 works by enhancing the body’s natural incretin system, increasing the levels of active incretin hormones that stimulate insulin secretion in response to elevated blood glucose levels. At the same time, it suppresses glucagon release, helping reduce glucose production by the liver. This glucose-dependent mechanism provides effective blood glucose control while minimizing the risk of hypoglycemia when used appropriately.

The medication may be prescribed as monotherapy or in combination with other oral antidiabetic medicines, including Metformin, sulfonylureas, thiazolidinediones, or insulin, depending on the patient’s clinical condition and treatment goals. It is commonly incorporated into comprehensive diabetes management plans alongside a balanced diet, regular physical activity, and routine blood glucose monitoring to achieve long-term glycemic control.

Manufactured under stringent pharmaceutical quality standards, Vildalip 50 delivers consistent efficacy, safety, and reliability, making it a trusted therapeutic option for healthcare professionals managing Type 2 Diabetes Mellitus.

How It Works

Vildagliptin inhibits the DPP-4 enzyme, preventing the breakdown of incretin hormones such as GLP-1 and GIP. Increased incretin levels stimulate glucose-dependent insulin secretion, suppress glucagon release, reduce hepatic glucose production, and help maintain stable fasting and postprandial blood glucose levels.

Therapeutic Applications

Vildalip 50 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Blood Glucose Control
• Long-Term Glycemic Management
• Combination Therapy with other Antidiabetic Medications
• Patients inadequately controlled by diet and exercise alone

Key Benefits

• Helps effectively lower fasting and postprandial blood glucose levels.
• Enhances glucose-dependent insulin secretion.
• Reduces glucagon secretion and hepatic glucose production.
• Low risk of hypoglycemia when used as prescribed.
• Suitable for monotherapy or combination antidiabetic therapy.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Vildalip 50 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Vildalip 50 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.